Liquidia wins against United Therapeutics in patent battle over PAH drug

01 Apr 2024

NDAPatent Infringement

United Therapeutics has suffered two court losses in its fight to keep a competitor for its blockbuster drug Tyvaso (treprostinil) from entering the market, with federal judges ruling in favor of Liquidia and the FDA in separate cases last week. Liquidia announced Monday that a federal judge in Delaware got rid of a 2022 injunction that was part of a patent lawsuit brought by United Therapeutics, finally allowing the FDA to approve Liquidia’s NDA for Yutrepia, its version of treprostinil, an inhaled powder that treats pulmonary arterial hypertension (PAH). With approval, Liquidia would be entering a blockbuster market: United said in its latest earnings that Tyvaso brought in $1.2 billion in sales in 2023, a 41% increase over the previous year.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Liquidia Corp.

United Therapeutics Corp.

US Food & Drug Administration

Indications

Pulmonary Arterial Hypertension

Targets

Drugs

Treprostinil

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.